EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression

Siyu Guo, Xiaodong Chen, Haojia Wang, Jiying Zhou, Peiying Lu, Jiangying Liu, Keyan Chai, Jingyuan Zhang, Siyun Yang, Shan Lu, Yifei Gao, Zhengsen Jin und 4 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202507008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Siyu Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Bufanolides, Breast Neoplasms, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project-Clinical Chinese Pharmacy, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer incidence is rising globally, presenting challenges such as treatment side effects and drug resistance. Bufalin is a bufadienolides compound with potential anti‐cancer effects. This study shows that bufalin inhibits malignant proliferation of MDA‐MB‐231 and MCF‐7 cells and protects mice against breast cancer. Of note, GTF3C4 was identified as the target protein by Limited Proteolysis‐Mass Spectrometry. GTF3C4 is overexpressed in breast cancer and associated with poor prognosis. RNA sequencing analysis reveals that the PI3K/AKT signaling pathway is a key contributor. Using cell thermal shift assays, drug affinity response target stability assays, and surface plasmon resonance, it was verified that bufalin can specifically bind to GTF3C4. Bufalin reduces GTF3C4 protein levels in vivo and in vitro, effectively inhibiting breast cancer progression by suppressing the PI3K/AKT signaling pathway. After the knockdown of GTF3C4, the PI3K/AKT signaling pathway is also suppressed, thereby inhibiting the proliferation of breast cancer cells and promoting apoptosis. Single‐cell RNA sequencing results indicated that bufalin reduces the proportions of macrophages, neutrophils, and monocytes, and affects the strength of receptor‐ligand signals between cells. Collectively, this study demonstrates that bufalin targets GTF3C4 to inhibit the PI3K/AKT pathway and remodels the tumor microenvironment, thereby hindering the malignant progression of breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BufanolidesBreast NeoplasmsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesHumansFemaleAnimalsMiceSignal TransductionCell ProliferationAntineoplastic AgentsCell Line, TumorDisease ProgressionMCF-7 CellsApoptosisMDA-MB-231 Cells

Stichwörter der Autor:innen

BufalinGTF3C4PI3K/AKT pathwaybreast cancertumor microenvironment

Substanzen

BufanolidesbufalinProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Modern Research Center For Traditional Chinese Medicine, Beijing Institute of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

ORCID-Profile: Jiarui Wu

Förderung

  • Beijing Natural Science Foundation
  • State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project-Clinical Chinese Pharmacy
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Guo, S., Chen, X., Wang, H., Zhou, J., Lu, P., Liu, J., Chai, K., Zhang, J., Yang, S., Lu, S., Gao, Y., Jin, Z., Tao, X., Hu, Z., Li, Q., & Wu, J. (2026). Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression. Advanced Science. https://doi.org/10.1002/advs.202507008

Vancouver

Guo S, Chen X, Wang H, Zhou J, Lu P, Liu J, et al. Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression. Advanced Science. 2026. doi:10.1002/advs.202507008

BibTeX
@article{Guo2026,
  author = {Guo, Siyu and Chen, Xiaodong and Wang, Haojia and Zhou, Jiying and Lu, Peiying and Liu, Jiangying and Chai, Keyan and Zhang, Jingyuan and Yang, Siyun and Lu, Shan and Gao, Yifei and Jin, Zhengsen and Tao, Xiaoyu and Hu, Zhongdong and Li, Qinglin and Wu, Jiarui},
  title = {Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202507008}
}
Kostenlos starten →